---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-087740"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T00:53:43.430110+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ABVC and BioLite license CNS drugs to AiBtl for 23M shares plus milestones; gains controlling interest

## Summary
- Licensed products (MDD and ADHD) valued at $667M by third-party evaluation.
- ABVC and BioLite each receive 23M shares of AIBL (targeted $10/share at IPO) within 30 days.
- Milestone payments of $3.5M and royalties of 5% of net sales, up to $100M.
- Share issuance gives ABVC controlling interest in AiBtl BioPharma Inc.

## SEC filing metadata
- accession: 0001213900-23-087740
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390023087740/0001213900-23-087740-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390023087740/ea188562-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-087740
- JSON: https://secwatch.observer/filing/0001213900-23-087740.json
- Plain text: https://secwatch.observer/filing/0001213900-23-087740.txt

## Key facts
- Material Agreements
  ABVC BIOPHARMA, INC. entered into a license with AiBtl BioPharma Inc. ("AIBL") valued at 23 million shares of AIBL stock ... $3,500,000 and royalties equaling 5% of net sales, up to $100 mi (effective 2023-11-12).
  - Action: entry
  - Agreement: license
  - Counterparty: AiBtl BioPharma Inc. ("AIBL")
  - Value: 23 million shares of AIBL stock ... $3,500,000 and royalties equaling 5% of net sales, up to $100 mi
  - Effective: 2023-11-12
  source text: In November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. ("BioLite") each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (" AIBL ") for the Company and BioLite’s CNS drugs
  evidence_url: https://www.sec.gov/Archives/edgar/data/1173313/000121390023087740/0001213900-23-087740-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.